Napo Pharmaceuticals Endorses Prevention Access Campaign’s U=U Consensus Statement for People Living With HIV/AIDS (PLWHA)
“Napo has been and continues to be an advocate for the HIV community and
their healthcare providers through our endorsement of the U=U Consensus
Statement, our sponsorship of the My
HIV Thank You platform, and our educational awareness programs. We
firmly believe that living with HIV requires access to the most
up-to-date research and experts,” said
“U=U is a life-changing message for people living with HIV but not
enough people know about it yet,” said
“Even though patients are undetectable, and cannot transmit the virus to
a partner, the effects of the virus on the GI tract, known as HIV
enteropathy, may remain in spite of viral suppression in the blood. CD4
counts are slower to recover in the gut and don’t recover to the same
level as in the plasma. HIV enteropathy is chronic persistent diarrhea
in PLWHA and is a problem that affects as many as twenty percent of HIV
patients,” stated Dr.
While Napo recognizes that many people living with HIV/AIDS are undetectable, one in five still suffer from diarrhea1.
Launched by Napo in
As announced last month, Napo significantly expanded its national
salesforce for Mytesi® through the recent hire in key U.S.
markets of six sales representatives experienced in the sale of drugs to
HIV physicians and gastroenterologists. With the equivalent of seven
dedicated, full-time sales representatives now reporting to a newly
hired national sales manager, supported by concomitant marketing,
promotional and medical education initiatives, Jaguar and Napo expect a
proportional response in the number of patients treated with Mytesi®.
Jaguar and Napo estimate the potential U.S. market for Mytesi®
to be approximately
To learn more about what you can do about HIV-related diarrhea, visit Mytesi.com.
For more information on the U=U campaign and to view a full list of partners click here.
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding Jaguar’s and Napo’s
belief that, with the equivalent of seven dedicated, full-time sales
representatives now reporting to a newly hired national sales manager,
supported by concomitant marketing, promotional and medical education
initiatives, there will be a proportional response in the number of
patients treated with Mytesi®, Jaguar’s and Napo’s estimate
that the potential U.S. market for Mytesi® is approximately
1Brenchley JM1, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008 Jan;1(1):23-30. doi: 10.1038/mi.2007.1.